Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors (Q40695402)

22 September 2017

title

Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors (English)

1 reference

22 September 2017

Peter L. Anderson

1

1 reference

22 September 2017

Courtney V. Fletcher

series ordinal

2

1 reference

22 September 2017

publication date

1 August 2001

1 reference

Current infectious disease reports

22 September 2017

published in

1 reference

22 September 2017

volume

3

1 reference

22 September 2017

issue

4

1 reference

22 September 2017

page(s)

381-387

1 reference

Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

22 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-001-0079-3

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-001-0079-3

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

12 December 2020

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

1 reference

12 December 2020

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

12 December 2020

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

12 December 2020

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture

1 reference

12 December 2020

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1 reference

12 December 2020

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.

1 reference

12 December 2020

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

12 December 2020

The triple combination indinavir-zidovudine-lamivudine is highly synergistic

1 reference

12 December 2020

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

12 December 2020

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

1 reference

12 December 2020

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

1 reference

12 December 2020

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

1 reference

12 December 2020

Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

1 reference

12 December 2020

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

1 reference

12 December 2020

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

1 reference

12 December 2020

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

1 reference

12 December 2020

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters

1 reference

12 December 2020

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

12 December 2020

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy

1 reference

12 December 2020

Natural history of HIV infection in the era of combination antiretroviral therapy

1 reference

12 December 2020

A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

1 reference

12 December 2020

Indinavir concentrations and antiviral effect

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

12 December 2020

Pharmacologic considerations for therapeutic success with antiretroviral agents

1 reference

12 December 2020

Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter

1 reference

12 December 2020

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

12 December 2020

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.

1 reference

12 December 2020

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

1 reference

12 December 2020

10.1007/S11908-001-0079-3

Identifiers

DOI

1 reference

22 September 2017

1 reference